WE CAN HELP
Book a FREE consultation  
For a free consultation or assistance, please call 020 7730 6666

Hair Loss Blog

Browse by Category

Belgravia Centre Hair Loss Treatment Before and After Results - New Success Story

alert alopecia areata the belgravia centre 17 09 2018A new entry has just been added to Belgravia’s Alopecia Areata Treatment Success Stories gallery.

Ms T, pictured, has responded really well to the treatment plan recommended by her specialist.

Read her Belgravia Centre review and see her regrowth results close up, or find out more about treating patchy hair loss from Alopecia Areata by clicking the relevant button below…

(Results may vary and are not guaranteed)

 

VIEW SUCCESS STORY

TreatmenT information 

 

 


The Belgravia Centre Hair Loss ClinicThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Just ten days after announcing having been awarded a Breakthrough Therapy designation by America’s Food and Drug Administration (FDA) for its novel Alopecia Areata treatment, Pfizer has revealed the results of its latest trial.

These were announced on 15th September 2018 as part of the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.

PfizerHair regrowth improvements

The multi-centre, blind Phase 2a clinical trial was conducted in a compared the effects of an oral janus kinase inhibitor (JAK inhibitor) known as PF-06651600, and a tyrosine kinase inhibitor referred to as PF-06700841, to a placebo in order to determine their hair regrowth capabilities. The trial participants all had confirmed diagnoses of autoimmune hair loss from moderate rounded bald patches of the scalp only (Alopecia Areata), to the most severe phenotype which presents as complete baldness from head to toe (Alopecia Universalis)

Although available Alopecia Areata treatment can be beneficial in cases of the localised scalp iteration – as many Belgravia clients have experienced – the more extensive the hair loss, the fewer and less effective current treatment options tend to be.

Trial volunteers were randomly split into three groups – one which received the JAK inhibitor PF-06651600, one which received the tyrosine kinase inhibitor PF-06700841 and one which received a placebo treatment.

The JAK inhibitor group was administered PF-06651600 in doses of 200 mg once per day for 4 weeks, then 50mg per day for 20 weeks. The PF-06700841 group were given the tyrosine kinase inhibitor in 60 mg per day doses for 4 weeks, followed by 30 mg daily for 20 weeks. Placebo doses were not provided but, equally, are irrelevant to the outcomes.

According to a press release circulated by the pharmaceutical giant, ‘the placebo-adjusted mean (95% CI) in SALT change from baseline scores at Week 24 were 33.6 points (21.4, 45.7), (P<0.0001) for PF-06651600 and 49.5 points (37.1, 61.8), (P<0.0001) for PF-06700841, with statistically significant separation from placebo occurring as early as Week 6 and Week 4, respectively.

Both JAK inhibitors met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline at week 24 (33.6 points and 49.5 points for JAK3 and TYK2/JAK1, respectively) as measured by the Severity of Alopecia Tool (SALT) score (100 point scale).’

Diagram Belgravia Centre Different Types of Alopecia Areata autoimmune hair loss

Areas affected by Alopecia Areata hair loss are shown in blue

Although there were some side effects noted, these adverse events were deemed ‘comparable between treatment groups’, with the most commonly seen issues being gastrointestinal and skin/subcutaneous tissue infections.

Dr. Michael Vincent, M.D, Ph.D., Senior Vice President and Chief Scientific Officer at Pfizer Inflammation and Immunology stated, “This is the first well-controlled study of oral JAK inhibitors in alopecia areata, helping enhance our understanding of this disease with significant unmet need and advance the science of kinase inhibition.

Whether he meant the first study by Pfizer, or in general – given that other research institutions and pharmaceutical companies have been conducting clinical trials into JAK inhibiton‘s effect on alopecia areata hair loss for some years now – was not made clear.

Moving on to next clinical trial phase

These results relate to completion of Phase 2a of the clinical trial process, which typically constitutes four separate stages – three prior to release, with the fourth being post-release monitoring. Therefore, Phase III is the final stage that, following successful completion, enables the drug to be put forward for evaluation by the necessary medical regulatory boards in each country, such as the MHRA and FDA in the UK and USA respectively. Their licenses and approvals need to be obtained before the medication can be made available for prescription to patients in those locations.

Given Pfizer and the FDA are working together to expedite the development and review processes involved in trying to bring these new treatments to market, although the process can take many months or years in some cases, this is likely to be prioritised in order to release the medications as quickly as possible if they are proven to meet all safety, tolerability and efficacy criteria.

The FDA is also working in a similar way with two other pharmaceutical companies to Fast Track their novel treatments for Alopecia Areata, Alopecia Totalis and Alopecia Universalis. The estimated release date that at least one of these is working towards, has been given as 2021/2022.

In the meantime, those affected with this type of alopecia are advised to consult their GP and look into support from counsellors and hair loss charities if the baldness extends to the whole head – including facial hair – or body, or if they are under 16 years of age. For those aged 16 and over with the scalp-only phenotype, topical treatment for Alopecia Areata may be possible, so a consultation with a hair specialist is worth considering.


Circ - Belgravia Centre Taxi New StreetThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Related Stories


Dealing with any type of hair loss can be hard to come to terms with, emotionally. Whilst friends and family may prove valuable sources of comfort, for some it can be helpful to speak with people who have been, or are going through, the same issue.

Sunderland-based organisation, Woman Warriors by Panache Group is a peer support group for women with various forms of Alopecia Areata, the autoimmune disorder which has left many of them completely bald. This fantastic community was founded by Jolene Casey and inspired by teen model Elisha Appleby who started losing her hair to this enigmatic condition at 15 years of age.

sherrie hewsonIn addition to helping each other, raising alopecia awareness and boosting their confidence – as well as visibility – via events such as walking in fashion shows, the Woman Warrior by Panache Group also aims to raise £100,000 to create a dedicated ‘hair loss hub’ in the North-East.

Now Newcastle-born Benidorm actor Sherrie Hewson has given them her backing after a chance meeting at a radio station.

Celebrity ambassador

Local newspaper, the Chronicle reports how warrior woman and Benidorm fan Hannah McKay ran into Hewson, in town to promote Benidorm Live at the Theatre Royal, when they were both being interviewed on Radio Newcastle.

McKay, who started to lose her hair in July 2017 and now has patchy hairloss from the scalp-only form of Alopecia Areata, was there to discuss Alopecia Awareness Month. She approached Hewson and the pair got chatting.

The candid star then opened up about her own experience of stress-related hair loss which she said caused her to lose the hair around her hairline and at the sides of her head. Although she did not state which hair loss condition she was affected by, she did note that it cleared up following six months of treatment, during which she wore wigs for her TV work.

“I lost my hair through stress and I know what they are dealing with and what they are going through,” Sherrie Hewson told the Chronicle.

“I understand their emotion and how it feels. A woman’s hair is their crown and glory, it’s your femininity and to lose it is very stressful. I know what it’s like to look in the mirror, I know what they are experiencing. 

These women are embracing their hair loss and by doing that and understanding it, then that helps them cope. It’s brilliant what they are doing and I’m happy to put my name to it.” Continues below…

Warrior Women Panache Group Hair Loss Support Group North East Sunderland Newcastle UK alopecia areata

Loose Women helping to dispel hair loss ‘stigma’

It seems fitting that Sherrie Hewson would agree to be an ambassador for such an organisation given she is one of a number of Loose Women panellists to open up about their hair loss.

Nadia Sawalha has discussed being diagnosed with the genetic condition Female Pattern Hair Loss, on the daytime TV show, whilst Gloria Hunniford has explained both the issues she had with thinning hair and the attitude her late daughter, Carol Keating, took after losing her hair during chemotherapy for breast cancer.

The popular programme has given prime coverage to various hair loss issues over the years, with presenters advising they want to help to eradicate the perceived stigma about women’s hair loss. A sentiment both the Loose Women and Warrior Women have in common.

Find out more about Woman Warriors by Panache Group and donate to their Just Giving campaign, via wearepanachegroup.com


CIRC Hair Vitalics for Women hair growth supplements Belgravia Centre womens hair loss treatmentThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Related Stories


Many women are now aware of the hair shedding associated with pregnancy – a temporary condition known as Postpartum Alopecia which occurs up to three months after giving birth. We would wager less are familiar with issues that – whilst mercifully rare – can cause hair loss whilst they are pregnant, however.

As part of Alopecia Awareness Month a teacher from Norfolk has chosen to speak out about losing her hair – including her eyelashes and eyebrows – following an ectopic pregnancy.

Surgery hospital medical operationTraumatic experience

Teacher-turned- medical tattooist and micropigmentation artist, Emma Holmes, spoke to Metro about how she went bald within a week. Despite suffering damage to her reproductive organs as a teenager, following a burst appendix, she later fell pregnant in 2009.

It was quickly discovered that she had an ectopic pregnancy, where the embryo forms outside the womb, and underwent keyhole surgery to remove one of her fallopian tubes, which caused her to lose the baby.

During this traumatic time Holmes, now 40, started experiencing significant and sudden hair loss, and her hair started falling out in clumps. This is a classic sign of the autoimmune disorder which presents as sudden, patchy hair fall, Alopecia Areata which disrupts the hair growth cycle, often temporarily but also, sometimes, on an on-going basis.

Struggling to understand and accept this shocking development, the Yorkshire woman sought advice and information from doctors but – given the enigmatic nature of Alopecia Areata and the fact it’s precise cause is still unknown – this proved fruitless.

I never really got an answer“, Emma told Metro. “The doctors just said that it was probably to do with a sudden change in my hormone levels after they removed my fallopian tube. Knowing that didn’t make it any better though.

Hormones or stress may be responsible

Hormonal fluctuations are known to be able to cause or exacerbate hair loss in women, though usually this presents as thinning hair rather than complete baldness.

Emma Holmes’ hairloss appears to be a result of Alopecia Areata – as senior Belgravia hair specialist, Leonora Doclis advises, “Based on her photographs published on news websites, it would appear she experienced diffuse Alopecia Areata – with patchy bald spots developing all over her scalp – to start, which then progressed to Alopecia Totalis. This is one of the most extreme phenotypes of Alopecia Areata, causing the scalp to become bald and often a loss of facial hair, including eyelashes and eyebrows, presenting simultaneously.

Alopecia Areata in all its forms is an autoimmune disorder which can be triggered by a number of factors including sudden shock, trauma – physical or emotional, severe stress, allergies, hormones, and a genetic element is also suspected though unconfirmed.

Although the scalp-only form can benefit from topical Alopecia Areata treatment, this cannot be used for the more severe forms. Nor can it be used during pregnancy or whilst nursing. There are a few Alopecia Totalis treatment options, including steroid injections – something Holmes is currently trying – and immunotherapy, though they tend to have low success rates.

The next four years are thought to be extremely exciting with regards developments in this arena, however, as three pharmaceutical companies each developing potential treatments for Alopecia Areata, Totalis and even the most severe iteration – Alopecia Universalis, which causes total baldness from head to toe, have now been awarded FDA fast track status. The anticipated release dates for these prescription medications is currently thought to be 2021/2022, and will mark the first clinically-proven drugs becoming available for the condition, providing viable options for people like Emma to regrow their hair.


Circ The Belgravia Centre Hair Loss Treatment for Alopecia AreataThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Related Stories


The latest development in what appears to be a three-way race to be the first pharmaceutical company to launch clinically-proven treatments for autoimmune hair loss, comes from Pfizer.

On 5th September 2018 Pfizer Inc. announced that the oral Janus kinase 3 (JAK3) inhibitor it is developing to treat all forms of Alopecia Areata, currently known as PF-06651600, has been designated as a Breakthrough Therapy by American regulatory body, the Food and Drug Administration (FDA).

This award was granted on the strength of the company’s Phase II clinical trial results which will be released publicly on 15th September 2018 at the European Academy of Dermatology and Venerology (EADV) Congress. Achieving this status means the development and reviews of the Phase III data, which is necessary in order to obtain the relevant FDA approvals needed to make the drug available for prescription, will be expedited in order to make it available as soon as possible.

Alopecia Areata treatment options

Alopecia Areata is an autoimmune disorder where immune cells in the body attack the hair follicles, leading to varying degrees of hair loss from hair bearing areas of the scalp and, in some cases, body. It can affect people of all ages, races and hair types and can be a one-off occurrence or may recur.

Alopecia Areata – both the name of the overarching group of conditions and that of the mildest form – causes patchy hairloss from the scalp only. This is seen as rounded bald spots and patches which may be one or many and as small as a coin or much, much bigger. When this type presents it will generally clear up of its own accord within 12 months, however, if or when this recovery will happen cannot be predicted.

Alopecia Totalis causes baldness of the scalp and may also involve the loss of facial hair, including eyelashes and eyebrows. Alopecia Universalis is the most severe form and results in a person becoming completely hairless from head to toe.

Whilst Alopecia Areata treatment options exist – and those for the scalp-only phenotype tend to have a more substantial success rate that the limited range of treatments for the more extreme iterations – they are not currently MHRA licensed nor FDA approved for the treatment of these conditions.

At Belgravia treatment for patchy hair loss of the scalp is offered to suitable over 16s, using personalised courses featuring a topical solution that is also used in the treatment of genetic hair loss. Although it has the relevant MHRA license and FDA approvals for this purpose only, it is widely understood by hair specialists to have beneficial applications outside of this scope, including for autoimmune alopecia. For children with any form and adults with Alopecia Totalis or Universalis, it is best to contact a dermatologist or doctor as many of the therapies, such as immunotherapy, are hospital-based.

FDA Breakthrough Therapy designation

Whilst some people may feel that baldness and hair loss are insignificant cosmetic issues, particularly as losing hair isn’t physically painful, this is far from true. Studies repeatedly find that people affected by any form of Alopecia Areata can experience high levels of mental anguish, with many being clinically diagnosed with psychological disorders including depression or anxiety as a result, especially in more severe cases of baldness.

food-and-drug-administration-usa-fdaThis is one of the major driving factors behind the FDA wanting to establish approved treatments to help those affected regrow their hair.

Due to this urgent need the FDA awarded two ‘Fast Track’ designations to companies developing drugs to meet these requirements, in the first half of 2018. The first went to Concert Pharmaceuticals in January 2018, then Aclaris Therapeutics in July 2018, both for their potential Alopecia Areata treatments using or based on JAK inhibition. Both have a portfolio of relevant patents for the drugs they are developing, though these seem to mostly apply to the USA and Japan.

Now Pfizer, which is the world’s largest pharmaceutical company, has been awarded a ‘Breakthrough Therapy designation’. The FDA initiated this type of award to expedite drug development and work closely with the relevant companies to ensure the reviews necessary to bring it to market happen as quickly as possible, in cases where a medication could be used ‘alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development’.

Pfizer has further advised in a press release that it is ‘also working with the European Medicines Agency (EMA) on the clinical development program’ for the PF-06651600 treatment.

Whether or not PF-06651600 is related to Pfizer’s existing JAK inhibitor drug, tofacitnib – brand name, Xeljanz – remains unconfirmed. However, this drug has been explored as a potential alopecia treatment by other researchers, with significant results, though concerns were raised regarding its safety profile. As a result, trials have been taking place that explore ways the deliver the drug, such as topical preparations rather than in an oral, tablet form, to help reduce these risks.

With three major players now having the FDA’s backing to help bring patients suitable treatments, proven via clinical trials to be safe, tolerable and effective, people with these conditions may have a wealth of options to choose from within the next four years.


circ - Belgravia Centre hair loss clinic London pharmacy hairloss treatmentsThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Related Stories


Over the years many studies have shown that men and women worry about how their looks affect how they’re seen at work and whether or they impact their career progression. For fashion models, however, image really is everything.

As the industry moves slowly towards becoming more inclusive and diverse, models with Alopecia Areata – an autoimmune disorder which causes varying degrees of hair loss – are stepping up. From fronting brand advertising and awareness campaigns to walking at New York Fashion Week, we look at some of the women seizing this moment.

Alopecia is Fashion campaign

Liverpool-based Claire Namukolo, who has experienced numerous hair loss conditions from thinning hair after giving birth – Postpartum Alopecia – to receding caused by tight hairstyles – Traction Alopecia, is the founder of hairloss charity, Hair Heals. It provides emotional and practical support to men, women and children who are losing their hair for any reason. She also organises Liverpool’s Urban Hair Show and came up with the idea of the #AlopeciaIsFashion campaign to promote alopecia awareness and push the message that ‘Alopecia is Fashion’ following her experiences in the industry.

She told the BBC, “We already have the standards that have been laid out within the fashion industry on what a model on the catwalk should look like, which are ‘you should have long hair, you should have nice hair.’ Fashion is alopecia, and we are going to use our campaign to blend it into the fashion industry and challenge perceptions.

Models Eve Betts from Wales and Nichola McAvoy from Manchester, who have both been bald since childhood and have no facial hair due to the more severe Alopecia Areata phenotypes, Alopecia Totalis and Alopecia Universalis, have joined forces with Namukolo. Their aim is to normalise hair loss within the fashion industry, which plays such a huge part in rolling messages out into wider society when it comes to how we look.

Jeana Turner Bald Model Alopecia Areata American Apparel hair lossThe campaign coincides with Alopecia Month – the annual event which, each September, helps to raise awareness specifically of autoimmune alopecia, following August which is considered general Hair Loss Month. As the term Alopecia technically just means ‘hair loss’ it is often confused with other conditions, when, in practice, it is used to refer specifically to autoimmune-related Alopecia Areata conditions and not, for example, hereditary issues such as Female Pattern Hair Loss (Androgenic Alopecia).

New York Fashion Week

One of the most famous female models with Alopecia Areata is Jeana Turner, a former America’s Next Top Model contestant who was encouraged to embrace her unique bald look by host Tyra Banks, in order to help her stand out. Her baldness was seen as an advantage, given it meant she could work her natural smooth look or wear wigs, depending on the job, which made her more versatile. Turner’s height – 5ft 6in, which is considered short for a model, especially when it comes to catwalk shows – was seen as a more limiting factor than her hair loss.

Despite not having an agent, the 25 year old has gone on to appear in numerous magazine features, music videos, and advertising campaigns – including the latest from American Apparel. She is now preparing to walk in various shows at New York Fashion Week for the second season in a row.

This increasing representation of people with hair loss – specifically bald women – in the media and fashion industry is exciting to see and can only be a positive thing, helping those affected to cope, as well as educating the public. To find out more about Alopecia Areata visit Belgravia’s dedicated section of blog articles, including various Alopecia Areata Treatment Success Stories featuring clients with the scalp-only phenotype.


Circ - The Belgravia Centre Treatment for Hair LossThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Related Stories


A Welshman recently featured in a number of British media stories after he lost a significant amount of weight and saw his white hair return to its natural colour.

But did losing weight really restore his hair’s natural brown pigmentation? A Belgravia hair specialist offers another possible explanation.

Alopecia Areata hair regrowth

Whilst many reports associated the return of his brunette shade to the 47 year old’s seven stone drop, the real reason is likely to be unrelated. Looking closer into stories about Brian Mcauley from South Wales, whose weight loss happened over seven months, it appears he had previous lost his hair to Alopecia Areata.

This is an autoimmune disorder which, due to a disruption in the hair growth cycle, causes sudden hair loss to varying degrees – from bald spots to complete hairlessness. It can affect any hair bearing areas of the head and body.

In the mildest form, where it affects only scalp hair, regrowth tends to occur naturally within 12 months in many cases. It is common for the hair to grow back white or colourless, but the natural pre-hairloss colouring should return within a few months.

Looking at photos of Mcauley in Metro and many other news publications, his hair was silver-white with no obvious signs of alopecia around seven months prior to losing weight. As such, it is likely to have simply been a coincidence that his Alopecia Areata recovery, in terms of pigmentation restoration, happened whilst he was also losing weight.

Hair growth and pigmentation

We asked Belgravia hair loss specialist, Rali Bozhinova to explain the science behind why hair can grow back white after Alopecia Areata.

The Anatomy of a Hair FollicleAt the very bottom of the hair bulb there is a structure called the dermal papilla and also the matrix. In these areas there are many stem cells which are constantly dividing and making up the hair. There are also melanocytes which are not dividing but they inject melanin – colour pigments – into keratinocytes in the hair, so this makes the hair to grow in the melanin-defined colour. As long as the melanocytes are functioning properly, the hair grows in the determined colour. When they stop functioning, we lose hair pigment,” she states.

During Alopecia Areata white blood cells are attacking that same part of the hair follicle – the bulb. Therefore, cells stop dividing and there is hair loss. There is also no more hair growth until the attack stops. Melanocytes are in the same area and can only inject melanin during the active growth phase – the Anagen stage of the hair growth cycle – and are, therefore, also affected whilst these attacks are happening.

When the attack stops and the hair starts growing back, it often returns without any pigment. There can be a bit of a delay in the melanocytes starting to inject melanin again. However, as long as the hair loss condition is no longer active and the hair keeps growing within its normal cycle, regular functioning of the melanocytes should return, restoring the hair’s previous pigmentation a short while later.”

Reassuring anyone concerned by white hair following autoimmune alopecia, Bozhinova confirms, “This is normal and we see it with most Belgravia patients with Alopecia Areata, regardless of their age, weight or medical history. It is obviously less noticeable, however, to those whose hair is grey or white already.


The Belgravia CentreThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Related Stories


Whilst August is now internationally recognised as ‘Hair Loss Month’, forms caused by autoimmune disorders belong to September, the annual Alopecia Awareness Month.

Alopecia Areata in all its various phenotypes is discussed and covered in the media more than normal throughout September, with a view to educating the public and supporting those experiencing this sudden hair loss.

Alopecia UK alopecia awareness month September 2018 This Is Me TwibbonEach year the leading UK hair loss charity, Alopecia UK also runs a campaign for the duration of the month, usually involving empowering and helping to provide a safe space for those affected.

Sharing selfies using #THISISME

The 2018 theme for Alopecia UK’s Alopecia Awareness Month activities is inspired by a song from top musical, The Greatest Showman. After hearing just how deeply the song about self-confidence and acceptance, ‘This is Me’ resonated with many community members, via the charity’s private Facebook page, the organisation decided to adopt the Keala Settle show tune to help inspire its members.

Taking inspiration from the line “I’m not scared to be seen, I make no apologies, this is me,” the charity is encouraging alopecians to open up and share selfies and videos on social media. All they ask is that they proudly display their authentic selves – with or without hats, wigs, scarves or makeup – and use the song title as its hashtag, #THISISME. You can hear the song and its powerful lyrics via the video below.

Alopecia UK has produced an easy-to-follow guide with ideas and helpful advice for to how to get involved, from adding a ‘This Is Me’ Twibbon to your Facebook or Twitter profile photos, to downloadable signs people can print off.

Sources of information on Alopecia Areata

Normal Hair Growth Cycle versus Hair Growth in Alopecia AreataAlopecia Areata – the group of conditions that range from Alopecia Areata (patchy hair loss of the scalp only) to Alopecia Universalis (complete baldness from head-to-toe) – can affect men, women and children of any age, race and hair type. They can occur when the hair growth cycle is disrupted and follicles which would otherwise be involved in normal, active hair production, shut down, becoming dormant. How long this inactivity will last is unknown and, even – as is the case with the majority of scalp-only cases – if the hair regrows naturally, it may recur at a later date.

Alopecia tends to come on suddenly, which can be especially traumatic, as can the fact that it is still somewhat enigmatic with the precise cause being unknown. Certain triggers have been identified, however, and include sudden shock, intense stress or trauma – such as a death or divorce – as well as certain allergies and a genetic element being suspected.

There are currently limited and largely unreliable treatment options for the most severe forms, though effective Alopecia Areata treatment is possible for the scalp-only form, particularly for adults aged 16 and over. For those wishing to find out more about these hair loss conditions, there are many online and physical resources but it is important to seek out respected, credible sources. The Belgravia hair loss blog has many articles that may be helpful in the Alopecia Areata section, whilst other reliable sources include the NHS website and specialist organisations’ sites, such as the Alopecia UK website.

For those aged 16 and over, if the shedding is from the scalp, a hair loss specialist is a good port of call as they will be able to assess the situation and tailor a custom treatment plan, where appropriate, as well as answer any questions.  For adults losing hair from all over their head – including facial hair, eyebrows, eyelashes etc – and under 16s with any type of sudden hair fall, a doctor or dermatologist is the best option for advice and information on potential treatments, whilst psychotherapy can also be beneficial in helping those affected to cope.


Circ The Belgravia Centre Hair Loss Treatment for Alopecia AreataThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Related Stories


American researchers from the University of Minnesota, in conjunction with the US’s National Alopecia Areata Foundation (NAAF), have registered a phase III clinical trial for a new type of topical immunotherapy in cases of extensive Alopecia Areata.
lotion topical cream ointment treatment

Diphenylcyclopropenone (DPCP), used in ointment form, will be used to treat 10 participants aged 18 and over, with 76%-99% hair loss of the scalp medically diagnosed to have been caused by this autoimmune disorder. The first part of the trial will be used to establish which strength(s) of the formulation is best to administer and investigate.

This follows the August 2018 findings of a systematic review into the efficacy of topical immunotherapy for all forms of autoimmune alopecia, uncovered by the Institute of Hair and Cosmetic Medicine at Yonsei University Wonju College of Medicine in Korea.

Testing the safety and efficacy of DPCP alopecia treatment

In order to assess the safety profile of DPCP as well as how effective the treatment may be, researchers will conduct trials using the following methodology, according to data found in the trial registration at clinicaltrials.gov:

‘All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2.

The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks.’

The study is not yet recruiting but hopes to start on 1st September 2018, with the final completion date currently estimated as 1st December 2019. This means a window of at least one-to-two years before the first JAK inhibitor treatments for Alopecia Areata – including its most severe phenotypes, Alopecia Totalis and Alopecia Universalis which cause baldness of the head and from head-to-toe, respectively – are estimated to become available for prescription.

Treating Alopecia Areata

At present, there are various Alopecia Areata treatment options for the scalp-only form, though the versions which affect other hair-bearing areas of the body have fewer choices. These range from various forms of topical immunotherapy to steroid treatments, though none have particularly significant success rates as yet. Whilst hair regrowth tends to occur naturally within 12 months, when it comes to the mildest form, this is not always the case and it is also less likely with the other, more extensive, forms.

When it comes to scalp-only Alopecia Areata, where bald spots suddenly appear – small or large, one or many – Belgravia offers adults aged 16 years and over, personalised courses featuring topical medications to help promote accelerated hair regrowth. These can be further buoyed by supplementary hair growth supporting products, depending on the needs and medical profile of the individual.

Children under 16 years of age with any form of autoimmune-related hairloss, and adults with the more extreme phenotypes, should speak to their GP or dermatologist for advice on their options. They may also find specialist hair loss charities, such as Alopecia UK, useful for both information and peer support.


circ - Belgravia Centre hair loss clinic London pharmacy hairloss treatmentsThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Related Stories


Regenerative scalp injections known as Platelet-Rich Plasma Therapy – or, more commonly – PRP, are now widely available and often marketed as a hair loss solution.

Whilst no clinical evidence has yet substantiated the claims that this course of treatment is effective in regrowing hair, it is still being investigated in relation to a number of hair loss conditions.

Most recently, Regeneris Medical has launched clinical trials into whether these injections – which involve taking a patient’s blood, separating it in a centrifuge, enriching it and injecting the solution back into their scalp – could treat Alopecia Areata and scarring alopecias, known as Cicatricial Alopecia

PRP Research Italy Feb 2017

PRP being administered for hair loss during a trial in Italy (February 2017)

Currently scalp-only Alopecia Areata treatment is possible and has been seen to produce significant results in many cases; the majority of conditions that fall under the Cicatricial Alopecia group, however, often cause permanent baldness due to hair follicles being destroyed and scalp scarring.

Trial methodology

The 60-person trial, registered at clinicaltrials.gov, goes by the official study title of Biocellular Regenerative Therapy in Treating Scarring Alopecias and Alopecia Areata: Use of High Density Platelet-Rich Plasma Concentrates and Cell-Enriched Emulsified Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF). It commenced on 17th February 2017 and hopes to have the relevant primary data collected by 22nd January 2019.

Participants involved in the trial, which is taking place at centres across the USA in California, Massachusetts and Montana, are men and women aged 18 to 75 years old with a medical diagnosis of Alopecia Areata or a form of Scarring Alopecia, as confirmed by a biopsy. Although the type of Alopecia Areata is unspecified, it is likely to be the scalp-only form, rather than the more extreme phenotypes of this autoimmune disorder.

Researchers’ aims are to discover the safety and efficacy of using a ‘biocellular mixture of emulsified adipose-derived tissue stromal vasular fraction (AD-tSVF) and high density PRP (HD-PRP)’. It has stated in trial literature that high density PRP concentrates, defined as more than 4-6 times the patient’s circulating baselines, have been recognised for their ability to stimulate the scalp tissues and hair follicles in cases of Androgenetic Alopecia (Male and Female Pattern Hair Loss).

Each of the 60 participants has adipose – body fat – taken via lipoaspiration (liposuction), and blood extracted for use in forming the PRP solutions. Then following procedures – featuring either active treatment or control placebos – are randomly allocated and carried out on the volunteers:

Group 1: HD-PRP + Matristem Matrix (ACell) scalp injections

Group 2: HD-PRP + Emulsified AD-tSVF scalp injections

Hair Loss Consultation Trichocheck at The Belgravia Centre

Group 3: tSVF, PRP, cSVF cell enriched biocellular therapeutic mix injected into the scalp

Group 4 (control): cSVF + Normal Saline (500cc) delivered via an IV

The team will first spend six months assessing any adverse effects, then – by using trichoscopy and photographic evidence – exploring hair growth and the general quality of the scalp hair, after 12 months of treatment. At this point, the researchers and patients will also provide their own assessments as to how treatment has gone.

Previous trials involving PRP

In April 2016 a Barcelona trial found that, whilst it was not sufficiently effective to be considered a hair loss treatment in its own right, PRP could be used as a secondary ‘booster’ therapy alongside clinically-proven medications for genetic hair loss. This was followed in December 2016 by news from a team of Egyptian researchers who found that PRP could be used to treat Alopecia Areata. It is likely this American research builds on these findings.

Treatments and controls used in this new trial are similar to those used in a 2016-2018 investigation into PRP for genetic hair loss, the results of which have not yet been announced. The University of Minnesota is also currently involved in a trial exploring PRP as a potential treatment for Frontal Fibrosing Alopecia – a type of Cicatricial Alopecia which mainly affects women and causes a thick band of baldness to develop around the hairline. Results from this study are expected in 2020.

This latest Regeneris trial is currently estimated to have final results by 22nd June 2019; once this information is released we will report back on the findings here on the Belgravia hair loss blog. In the meantime, anyone concerned about sudden hair loss, unusual levels of hair fall or thinning hair should contact a specialist to receive a timely diagnosis.


The Belgravia CentreThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.


Related Stories